Therapeutic Approaches to Aging - Reply

Tamara Tchkonia; James L. Kirkland

doi:10.1001/jama.2018.20554

Therapeutic Approaches to Aging - Reply

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	901-902
Number of pages	2
Journal	JAMA - Journal of the American Medical Association
Volume	321
Issue number	9
DOIs	https://doi.org/10.1001/jama.2018.20554
State	Published - Mar 5 2019

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1001/jama.2018.20554

Cite this

@article{65ae1a663ab6426aac154c70ce7fe0a1,

title = "Therapeutic Approaches to Aging - Reply",

author = "Tamara Tchkonia and Kirkland, {James L.}",

note = "Funding Information: Conflict of Interest Disclosures: Drs Tchkonia and Kirkland reported receiving grants from the National Institutes of Health, the Connor Group, the Noaber Foundation, Robert J. and Theresa W. Ryan, and the Ted Nash Long Life Foundation as well as a BIG Award from the Glenn Foundation for Medical Research in partnership with the American Federation for Aging Research. Drs Tchkonia and Kirkland also reported holding a patent on senolytic drugs assigned to Mayo Clinic and that Mayo Clinic licensed to Unity Biotechnology and having received shares in Unity Biotechnology related to this patent. 1. Tchkonia T, Kirkland JL. Aging, cell senescence, and chronic disease: emerging therapeutic strategies. JAMA. 2018;320(13):1319-1320. doi:10.1001/ jama.2018.12440 2. Zhu Y, Tchkonia T, Pirtskhalava T, et al. The Achilles{\textquoteright} heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. 2015;14(4):644-658. doi:10. 1111/acel.12344 3. Kirkland JL, Tchkonia T. Cellular senescence: a translational perspective. EBioMedicine. 2017;21:21-28. doi:10.1016/j.ebiom.2017.04.013 4. Xu M, Pirtskhalava T, Farr JN, et al. Senolytics improve physical function and increase lifespan in old age. Nat Med. 2018;24(8):1246-1256. doi:10.1038/ s41591-018-0092-9 5. Zhu Y, Tchkonia T, Fuhrmann-Stroissnigg H, et al. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors. Aging Cell. 2016;15(3):428-435. doi:10.1111/acel.12445 6. Wilson WH, O{\textquoteright}Connor OA, Czuczman MS, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010;11(12):1149-1159. doi:10.1016/S1470-2045(10)70261-8",

year = "2019",

month = mar,

day = "5",

doi = "10.1001/jama.2018.20554",

language = "English (US)",

volume = "321",

pages = "901--902",

journal = "JAMA - Journal of the American Medical Association",

issn = "0098-7484",

publisher = "American Medical Association",

number = "9",

}

TY - JOUR

T1 - Therapeutic Approaches to Aging - Reply

AU - Tchkonia, Tamara

AU - Kirkland, James L.

N1 - Funding Information: Conflict of Interest Disclosures: Drs Tchkonia and Kirkland reported receiving grants from the National Institutes of Health, the Connor Group, the Noaber Foundation, Robert J. and Theresa W. Ryan, and the Ted Nash Long Life Foundation as well as a BIG Award from the Glenn Foundation for Medical Research in partnership with the American Federation for Aging Research. Drs Tchkonia and Kirkland also reported holding a patent on senolytic drugs assigned to Mayo Clinic and that Mayo Clinic licensed to Unity Biotechnology and having received shares in Unity Biotechnology related to this patent. 1. Tchkonia T, Kirkland JL. Aging, cell senescence, and chronic disease: emerging therapeutic strategies. JAMA. 2018;320(13):1319-1320. doi:10.1001/ jama.2018.12440 2. Zhu Y, Tchkonia T, Pirtskhalava T, et al. The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. 2015;14(4):644-658. doi:10. 1111/acel.12344 3. Kirkland JL, Tchkonia T. Cellular senescence: a translational perspective. EBioMedicine. 2017;21:21-28. doi:10.1016/j.ebiom.2017.04.013 4. Xu M, Pirtskhalava T, Farr JN, et al. Senolytics improve physical function and increase lifespan in old age. Nat Med. 2018;24(8):1246-1256. doi:10.1038/ s41591-018-0092-9 5. Zhu Y, Tchkonia T, Fuhrmann-Stroissnigg H, et al. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors. Aging Cell. 2016;15(3):428-435. doi:10.1111/acel.12445 6. Wilson WH, O’Connor OA, Czuczman MS, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010;11(12):1149-1159. doi:10.1016/S1470-2045(10)70261-8

PY - 2019/3/5

Y1 - 2019/3/5

UR - http://www.scopus.com/inward/record.url?scp=85062331771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062331771&partnerID=8YFLogxK

U2 - 10.1001/jama.2018.20554

DO - 10.1001/jama.2018.20554

M3 - Letter

C2 - 30835305

AN - SCOPUS:85062331771

SN - 0098-7484

VL - 321

SP - 901

EP - 902

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

IS - 9

ER -

Therapeutic Approaches to Aging - Reply

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this